Epileptic seizures manifest as the first presenting symptom before a primary brain tumor diagnosis in approximately 30-60 % of patients. These seizures directly impact the quality of life and confer higher risks for seizure-related complications. Low-grade tumors (i.e. oligodendrogliomas, astrocytoma) have a higher seizure incidence when compared to high-grade tumors (i.e glioblastoma) and metastatic tumors. Denervation hypersensitivity and impairments in the subcortical network have been suggested as some reasons accounting for seizure onset. While surgery, radiotherapy, and chemotherapy have been shown to achieve seizure control, brain-tumor-related epilepsies appear refractory to antiepileptic treatments. Tumor type, WHO grade, and location are some of the key factors influencing the incidence, resistance, and frequency of seizures.
Understanding the molecular mechanisms behind the pathogenesis shed light on current treatments and management of patients. Moreover, the impact of antitumor therapy on seizure control, and symptomatic management of anticonvulsants must also be considered. Our goal in this collection is to bring together the most up-to-date advances in the field from the bench to the bedside.
The goal of this series is to collect and highlight a comprehensive set of articles that show advancements in the field of seizure in intracranial tumors in the last decade. It will be an objective of this collection to inform, inspire, and provide a direction for future research as it primarily relates to the practice of neurosurgery and is secondarily informed by the disciplines of neurology, molecular neurobiology, systems neuroscience, psychiatry, neuroimaging, neuro-oncology, and palliative care.
In this collection, we welcome original research articles, case reports, meta-analyses, literature and systematic reviews, and clinical trials. While not an exhaustive list, many of the key topics we plan to cover include the molecular pathophysiology landscape, assessing the efficacy and choices of anti-epileptic drugs in control and survival of low and high-grade tumors, anticonvulsive prophylaxis use, postoperative progression of patients, predictors of seizure freedom, prognostic values of EEGs, neurological and psychiatric manifestations in patients, cognitive impacts of seizure burden in tumor patients, and employing radiotherapy/chemotherapy approach for seizure treatment.
Epileptic seizures manifest as the first presenting symptom before a primary brain tumor diagnosis in approximately 30-60 % of patients. These seizures directly impact the quality of life and confer higher risks for seizure-related complications. Low-grade tumors (i.e. oligodendrogliomas, astrocytoma) have a higher seizure incidence when compared to high-grade tumors (i.e glioblastoma) and metastatic tumors. Denervation hypersensitivity and impairments in the subcortical network have been suggested as some reasons accounting for seizure onset. While surgery, radiotherapy, and chemotherapy have been shown to achieve seizure control, brain-tumor-related epilepsies appear refractory to antiepileptic treatments. Tumor type, WHO grade, and location are some of the key factors influencing the incidence, resistance, and frequency of seizures.
Understanding the molecular mechanisms behind the pathogenesis shed light on current treatments and management of patients. Moreover, the impact of antitumor therapy on seizure control, and symptomatic management of anticonvulsants must also be considered. Our goal in this collection is to bring together the most up-to-date advances in the field from the bench to the bedside.
The goal of this series is to collect and highlight a comprehensive set of articles that show advancements in the field of seizure in intracranial tumors in the last decade. It will be an objective of this collection to inform, inspire, and provide a direction for future research as it primarily relates to the practice of neurosurgery and is secondarily informed by the disciplines of neurology, molecular neurobiology, systems neuroscience, psychiatry, neuroimaging, neuro-oncology, and palliative care.
In this collection, we welcome original research articles, case reports, meta-analyses, literature and systematic reviews, and clinical trials. While not an exhaustive list, many of the key topics we plan to cover include the molecular pathophysiology landscape, assessing the efficacy and choices of anti-epileptic drugs in control and survival of low and high-grade tumors, anticonvulsive prophylaxis use, postoperative progression of patients, predictors of seizure freedom, prognostic values of EEGs, neurological and psychiatric manifestations in patients, cognitive impacts of seizure burden in tumor patients, and employing radiotherapy/chemotherapy approach for seizure treatment.
